{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:39:55Z","timestamp":1792445995655,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03170-3","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:06:40Z","timestamp":1792400800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the mitochondrial complex I subunit NDUFS2 potentiates FLT3 inhibition in acute myeloid leukaemia with FLT3 internal tandem duplication"],"prefix":"10.1038","author":[{"given":"Xiqin","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0982-0382","authenticated-orcid":false,"given":"Fuling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"3170_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"N Daver","year":"2021","unstructured":"Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021;11:104.","journal-title":"Blood Cancer J"},{"key":"3170_CR2","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1182\/blood.2021011583","volume":"139","author":"AE Perl","year":"2022","unstructured":"Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, et al. Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022;139:3366\u201375.","journal-title":"Blood"},{"key":"3170_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-024-01617-7","volume":"17","author":"J Cortes","year":"2024","unstructured":"Cortes J. Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML. J Hematol Oncol. 2024;17:111.","journal-title":"J Hematol Oncol"},{"key":"3170_CR4","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728\u201340.","journal-title":"N Engl J Med"},{"key":"3170_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41375-022-01742-7","volume":"37","author":"PY Dumas","year":"2023","unstructured":"Dumas PY, Raffoux E, B\u00e9rard E, Bertoli S, Hospital MA, Heiblig M, et al. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA\/FILO. Leukemia. 2023;37:91\u2013101.","journal-title":"Leukemia"},{"key":"3170_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104424","volume":"201","author":"M Ruglioni","year":"2024","unstructured":"Ruglioni M, Crucitta S, Luculli GI, Tancredi G, Del Giudice ML, Mechelli S, et al. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy. Crit Rev Oncol Hematol. 2024;201:104424.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3170_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00687-5","volume":"12","author":"SP Desikan","year":"2022","unstructured":"Desikan SP, Daver N, DiNardo C, Kadia T, Konopleva M, Ravandi F. Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer J. 2022;12:91.","journal-title":"Blood Cancer J"},{"key":"3170_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101286","volume":"83","author":"F Song","year":"2025","unstructured":"Song F, Lin S, Xu T, Yang C, Sharavyn B, Naranmandura H, et al. Targeted therapy in acute myeloid leukemia: resistance and overcoming strategies. Drug Resist Update. 2025;83:101286.","journal-title":"Drug Resist Update"},{"key":"3170_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100853","volume":"64","author":"M \u015aniegocka","year":"2022","unstructured":"\u015aniegocka M, Liccardo F, Fazi F, Masciarelli S. Understanding ER homeostasis and the UPR to enhance treatment efficacy of acute myeloid leukemia. Drug Resist Update. 2022;64:100853.","journal-title":"Drug Resist Update"},{"key":"3170_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","volume":"10","author":"H Du","year":"2025","unstructured":"Du H, Xu T, Yu S, Wu S, Zhang J. Mitochondrial metabolism and cancer therapeutic innovation. Signal Transduct Target Ther. 2025;10:245.","journal-title":"Signal Transduct Target Ther"},{"key":"3170_CR11","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/s41418-022-01022-y","volume":"29","author":"L Sainero-Alcolado","year":"2022","unstructured":"Sainero-Alcolado L, Lia\u00f1o-Pons J, Ruiz-P\u00e9rez MV, Arsenian-Henriksson M. Targeting mitochondrial metabolism for precision medicine in cancer. Cell Death Differ. 2022;29:1304\u201317.","journal-title":"Cell Death Differ"},{"key":"3170_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-021-01416-w","volume":"36","author":"L de Beauchamp","year":"2022","unstructured":"de Beauchamp L, Himonas E, Helgason GV. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia. 2022;36:1\u201312.","journal-title":"Leukemia"},{"key":"3170_CR13","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1182\/blood-2017-12-820035","volume":"131","author":"P Gallipoli","year":"2018","unstructured":"Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, et al. Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood. 2018;131:1639\u201353.","journal-title":"Blood"},{"key":"3170_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abp9005","volume":"8","author":"P Zhang","year":"2022","unstructured":"Zhang P, Brinton LT, Gharghabi M, Sher S, Williams K, Cannon M, et al. Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor-mediated synergistic antileukemic actions. Sci Adv. 2022;8:eabp9005.","journal-title":"Sci Adv"},{"key":"3170_CR15","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.79940","volume":"11","author":"HJ Park","year":"2022","unstructured":"Park HJ, Gregory MA, Zaberezhnyy V, Goodspeed A, Jordan CT, Kieft JS, et al. Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM\/mTOR pathway regulating oxidative phosphorylation. Elife. 2022;11:e79940.","journal-title":"Elife"},{"key":"3170_CR16","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1158\/1078-0432.CCR-14-2146","volume":"21","author":"F Alvarez-Calderon","year":"2015","unstructured":"Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, et al. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res. 2015;21:1360\u201372.","journal-title":"Clin Cancer Res"},{"key":"3170_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41392-025-02303-x","volume":"10","author":"DA Pereira-Martins","year":"2025","unstructured":"Pereira-Martins DA, Weinh\u00e4user I, Griessinger E, Coelho-Silva JL, Silveira DR, Sternadt D, et al. High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerability. Signal Transduct Target Ther. 2025;10:222.","journal-title":"Signal Transduct Target Ther"},{"key":"3170_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40170-021-00253-w","volume":"9","author":"SB Panina","year":"2021","unstructured":"Panina SB, Pei J, Kirienko NV. Mitochondrial metabolism as a target for acute myeloid leukemia treatment. Cancer Metab. 2021;9:17.","journal-title":"Cancer Metab"},{"key":"3170_CR19","first-page":"2647","volume":"110","author":"J Ikeda","year":"2025","unstructured":"Ikeda J, Kunimoto H, Saito Y, Tsujimoto SI, Takeuchi M, Miura A, et al. Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia. Haematologica. 2025;110:2647\u201360.","journal-title":"Haematologica"},{"key":"3170_CR20","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","volume":"28","author":"T Haferlach","year":"2010","unstructured":"Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, B\u00e9n\u00e9 MC, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010;28:2529\u201337.","journal-title":"J Clin Oncol"},{"key":"3170_CR21","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1365-2141.2008.07261.x","volume":"142","author":"A Kohlmann","year":"2008","unstructured":"Kohlmann A, Kipps TJ, Rassenti LZ, Downing JR, Shurtleff SA, Mills KI, et al. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br J Haematol. 2008;142:802\u20137.","journal-title":"Br J Haematol"},{"key":"3170_CR22","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.cell.2016.11.012","volume":"167","author":"M Wu","year":"2016","unstructured":"Wu M, Gu J, Guo R, Huang Y, Yang M. Structure of mammalian respiratory supercomplex I(1)III(2)IV(1). Cell. 2016;167:1598\u2013609.e10.","journal-title":"Cell"},{"key":"3170_CR23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200924","volume":"218","author":"L Stuani","year":"2021","unstructured":"Stuani L, Sabatier M, Saland E, Cognet G, Poupin N, Bosc C, et al. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. J Exp Med. 2021;218:e20200924.","journal-title":"J Exp Med"},{"key":"3170_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12:329\u201341.","journal-title":"Cell Stem Cell"},{"key":"3170_CR25","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24:1859\u201366.","journal-title":"Nat Med"},{"key":"3170_CR26","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D\u2019Alessandro A, Winters A, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1:1176\u201387.","journal-title":"Nat Cancer"},{"key":"3170_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312.","journal-title":"Leukemia"},{"key":"3170_CR28","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","volume":"24","author":"JR Molina","year":"2018","unstructured":"Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24:1036\u201346.","journal-title":"Nat Med"},{"key":"3170_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115219","volume":"251","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Zou J, Xu J, Zhou Y, Cen X, Zhao Y. Recent advances of mitochondrial complex I inhibitors for cancer therapy: current status and future perspectives. Eur J Med Chem. 2023;251:115219.","journal-title":"Eur J Med Chem"},{"key":"3170_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.686765","volume":"11","author":"X Lu","year":"2021","unstructured":"Lu X, Han L, Busquets J, Collins M, Lodi A, Marszalek JR, et al. The combined treatment with the FLT3-inhibitor AC220 and the complex I inhibitor IACS-010759 synergistically depletes Wt- and FLT3-mutated acute myeloid leukemia cells. Front Oncol. 2021;11:686765.","journal-title":"Front Oncol"},{"key":"3170_CR31","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/s41375-024-02292-w","volume":"38","author":"R Zhu","year":"2024","unstructured":"Zhu R, Shirley CM, Chu SH, Li L, Nguyen BH, Seo J, et al. Inhibition of NOTCH4 sensitizes FLT3\/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition. Leukemia. 2024;38:1581\u201391.","journal-title":"Leukemia"},{"key":"3170_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56520-7","volume":"16","author":"X Sun","year":"2025","unstructured":"Sun X, Li Y, Du J, Liu F, Wu C, Xiao W, et al. Targeting ceramide transfer protein sensitizes AML to FLT3 inhibitors via a GRP78-ATF6-CHOP axis. Nat Commun. 2025;16:1358.","journal-title":"Nat Commun"},{"key":"3170_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110197","volume":"38","author":"A Grenier","year":"2022","unstructured":"Grenier A, Poulain L, Mondesir J, Jacquel A, Bosc C, Stuani L, et al. AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia. Cell Rep. 2022;38:110197.","journal-title":"Cell Rep"},{"key":"3170_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, et al. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023;29:115\u201326.","journal-title":"Nat Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03170-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03170-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03170-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:01:25Z","timestamp":1792443685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03170-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":34,"alternative-id":["3170"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03170-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}